HN2002000045A -
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
- Google Patents
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inc PfizerfiledCriticalInc Pfizer
Priority to HN2002000045ApriorityCriticalpatent/HN2002000045A/en
Publication of HN2002000045ApublicationCriticalpatent/HN2002000045A/en
LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y/O EL TRATAMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA EN UN MAMIFERO, QUE COMPRENDEN AGONISTAS INVERSOS DE GABA EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA (NRPA), ESTROGENOS (SERMS) O VITAMINA E, Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE.THE PRESENT INVENTION REFERS TO PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF COGNITIVE DYSFUNCTION DISEASES IN A MAMMER, WHICH INCLUDE GABA INVESTED AGONISTS IN COMBINATION WITH PARTIAL AGONISTS OF NICOTINAG RECEPTOR (NICOTAMIN SERG) E, AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE.
HN2002000045A2002-02-282002-02-28
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
HN2002000045A
(en)
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
USE OF INVESTED AGONISTS GABA IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEPTOR, STROGENS, SELECTIVE MODULATORS OF STROGENS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
USE OF GABAA INVESTED AGONISTS IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEIVER, ESTRÓGENOS, SELECTIVE MODULATORS OF ESTRÓGENOS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.
PHARMACEUTICAL LIBERATION SYSTEM THAT INCLUDES FLIBANSERINE AND AT LEAST AN ACCEPTABLE PHARMACEUTICALLY EXCIPIENT; AND ITS USE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEMS, AFFECTIVE, SOUND AND SEXUAL DISORDERS, AMONG OTHERS.
Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others.
PHARMACEUTICAL COMPOSITIONS TO TREAT SKIN DISEASES THAT INCLUDE A COMBINATION OF EPINASTINE AND ONE OR MORE ADDITIONAL MINERALS OR ONE OR MORE GROSS PHARMACOS